CJC-1295 + Ipamorelin + Tesamorelin + IGF-1 LR3 Stack Guide

This 4-peptide stack is effective because it attacks the GH/IGF-1 axis from every available angle. Rather than relying on a single mechanism, it combines four distinct pathways that amplify each other.

Pathway 1: GHRH Amplification (CJC-1295)

• GHRH analog: CJC-1295 mimics Growth Hormone Releasing Hormone, amplifying and extending the natural GH pulse from the pituitary
• Extended half-life: with DAC modification, CJC-1295 provides sustained GH elevation over days rather than minutes, raising baseline GH output
• Synergy with GHRP: GHRH analogs are significantly more effective when paired with a GHRP (like Ipamorelin), as they work on complementary receptor pathways

Pathway 2: GH Release Trigger (Ipamorelin)

• Ghrelin mimetic (GHRP): Ipamorelin activates the GHS-R (growth hormone secretagogue receptor) to trigger direct GH release from the pituitary
• Selective action: unlike GHRP-6 or Hexarelin, Ipamorelin does not significantly increase cortisol, prolactin, or appetite — making it the cleanest GHRP option
• Pulse amplification: when combined with CJC-1295 (GHRH), the GH pulse is dramatically larger than either compound alone — this is the foundational synergy of the stack

Pathway 3: Visceral Fat Targeting (Tesamorelin)

• Modified GHRH(1-44): Tesamorelin is a 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification that provides enhanced stability and specific visceral fat targeting
• FDA-studied efficacy: clinical trials in HIV-associated lipodystrophy demonstrated significant visceral adipose tissue reduction over 26 weeks
• Complementary to CJC-1295: while both are GHRH-based, Tesamorelin provides targeted visceral fat signaling that CJC-1295 alone does not achieve as effectively

Pathway 4: Direct IGF-1 Receptor Activation (IGF-1 LR3)

• Bypasses the pituitary: while the three secretagogues stimulate GH release (which the liver then converts to IGF-1), IGF-1 LR3 provides direct IGF-1 receptor activation without waiting for that conversion
• Extended half-life: the LR3 modification (Long-Arg3) reduces IGF binding protein affinity, extending the active half-life to 20–30 hours compared to minutes for native IGF-1
• Anabolic signaling: directly stimulates muscle protein synthesis, satellite cell activation, and nutrient partitioning independent of GH levels

The Synergy

CJC-1295 + Ipamorelin create amplified GH pulses (upstream). Tesamorelin adds a parallel GHRH signal with specific visceral fat targeting. IGF-1 LR3 provides direct downstream anabolic signaling that does not depend on the GH-to-IGF-1 conversion pathway. The result is simultaneous stimulation of the GH/IGF-1 axis from both above (secretagogue-driven GH) and below (direct IGF-1), plus targeted visceral fat reduction — a combination no single compound or simpler stack can replicate.

This stack uses two separate injection sessions per day: GH secretagogues together before bed, and IGF-1 LR3 at a different time. The protocol is phased to allow gradual introduction of each compound.

Full Protocol (Phased Introduction)

Individual Dose Summary

All four peptides follow the same reconstitution process. Reconstitute each vial separately with bacteriostatic water. IGF-1 LR3 is particularly sensitive to heat and agitation — handle it with extra care.

For a detailed visual walkthrough, see our Reconstitution Guide.

This stack uses staggered cycling: the GH secretagogues run for the full 8–12 week duration while IGF-1 LR3 is introduced for a limited 4–6 week window within that period.

Why Stagger IGF-1 LR3?

• Receptor desensitization: Continuous IGF-1 LR3 use beyond 4–6 weeks can lead to IGF-1 receptor downregulation, reducing effectiveness
• Safety window: Limiting the duration of direct IGF-1 receptor activation reduces cumulative hypoglycemia risk and limits the time spent at supraphysiological IGF-1 levels
• Bloodwork timing: Introducing IGF-1 LR3 at week 5 means your week-4 bloodwork captures the secretagogue-only baseline, and week-8 bloodwork captures the full stack effect

Why the Break is Non-Negotiable

The 4–8 week break between cycles serves several critical purposes: (1) allows the GH/IGF-1 axis to return to baseline, (2) permits assessment of sustained body composition changes versus transient effects like water retention, (3) gives the IGF-1 receptor time to fully resensitize, and (4) reduces cumulative exposure to supraphysiological hormone levels. Do not skip the break.

Common Side Effects

• Water retention and bloating — common with elevated GH; typically most noticeable in the first 2–4 weeks and in hands/face
• Joint pain and stiffness — from elevated GH, often in wrists and fingers; usually dose-dependent
• Carpal tunnel symptoms — tingling or numbness in hands; a well-known GH-related side effect that resolves with dose reduction
• Hypoglycemia (from IGF-1 LR3) — shakiness, sweating, dizziness, confusion; manage with fast-acting carbs; most acute in first 1–2 hours post-injection
• Injection site redness or swelling — common with SubQ injections; rotate injection sites
• Increased hunger — from GH elevation and IGF-1 signaling; can be beneficial for muscle gain goals
• Transient headache — usually in the first week; typically resolves
• Vivid dreams and improved sleep quality — from the evening GH pulse; generally considered a positive effect

Serious Risks

• Insulin resistance: Sustained GH elevation antagonizes insulin action. Combined with IGF-1 LR3's glucose-lowering effect, this creates a complex metabolic environment that requires monitoring.
• Supraphysiological IGF-1 levels: Chronically elevated IGF-1 above the normal range is associated with increased cancer risk in epidemiological studies. This is the primary long-term concern with aggressive GH/IGF-1 stacks.
• Acute hypoglycemia: IGF-1 LR3 can cause blood sugar drops serious enough to cause confusion, loss of consciousness, or worse — especially at higher doses without carbohydrate intake.

Absolute Contraindications

• Active cancer or history of cancer: This stack elevates both GH and IGF-1, both of which promote cell proliferation and angiogenesis. Absolutely contraindicated with any malignancy, current or historical.
• Diabetes (Type 1 or uncontrolled Type 2): The combination of GH-driven insulin resistance and IGF-1 LR3-driven hypoglycemia creates dangerous glucose instability.
• Pregnancy and breastfeeding: No safety data exists for any component during pregnancy. Avoid entirely.
• Active pituitary disorders: GH secretagogues stimulate the pituitary and should not be used with pituitary tumors or other pituitary pathology.
• Under 25 years old: Open growth plates and developing endocrine systems make GH/IGF-1 manipulation particularly risky in younger individuals.

Stack-Specific Safety Notes

• Additive GH stimulation: Three secretagogues simultaneously produce higher GH output than any two. Side effects are dose-dependent — if you experience water retention or joint pain, reduce the Ipamorelin or Tesamorelin dose first.
• Opposing glucose effects: GH raises blood sugar (insulin antagonist) while IGF-1 LR3 lowers it. This does NOT mean they cancel out — they create unpredictable glucose dynamics that require monitoring.
• Separate syringes: Use a dedicated syringe for each peptide to avoid compatibility issues in solution.